Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 24 Jun 2026, 19:19.
ORBIMED ADVISORS LLC - 22 Jun 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ELVN
- Reported as of
- 22 Jun 2026
- Net transaction value
- -$39,014,046
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2026, 19:19:54 UTC
- Prior SEC filing
- 17 Jun 2026
- Next SEC filing
- 02 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 24 Jun 2026.
Change
- Previous filing in this sequence was filed on 17 Jun 2026.
- Current net transaction value: -$39,014,046.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (3)
CIK 0001055951
Primary reporting owner
ORBIMED ADVISORS LLC
- Relationship
- 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
- Signature date
- 22 Jun 2026
CIK 0001760648
OrbiMed Capital GP VII LLC
- Relationship
- 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Capital GP VII LLC
- Signature date
- 22 Jun 2026
CIK 0001808744
OrbiMed Genesis GP LLC
- Relationship
- 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Genesis GP LLC
- Signature date
- 22 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELVN
transaction
Common Stock
Sale
- Transaction value
- $1,127,511
- Shares
- -24,846
- Change %
- -10%
- Price
- $45.38
- Shares after
- 220,882
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $1,127,511
- Shares
- -24,846
- Change %
- -10%
- Price
- $45.38
- Shares after
- 220,882
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $1,127,511
- Shares
- -24,846
- Change %
- -10%
- Price
- $45.38
- Shares after
- 220,882
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $66,465
- Shares
- -1,477
- Change %
- -0.67%
- Price
- $45.00
- Shares after
- 219,405
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $66,465
- Shares
- -1,477
- Change %
- -0.67%
- Price
- $45.00
- Shares after
- 219,405
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $66,465
- Shares
- -1,477
- Change %
- -0.67%
- Price
- $45.00
- Shares after
- 219,405
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F1, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $35,715,149
- Shares
- -787,024
- Change %
- -11%
- Price
- $45.38
- Shares after
- 6,601,878
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $35,715,149
- Shares
- -787,024
- Change %
- -11%
- Price
- $45.38
- Shares after
- 6,601,878
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $35,715,149
- Shares
- -787,024
- Change %
- -11%
- Price
- $45.38
- Shares after
- 6,601,878
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $2,104,920
- Shares
- -46,776
- Change %
- -0.71%
- Price
- $45.00
- Shares after
- 6,555,102
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $2,104,920
- Shares
- -46,776
- Change %
- -0.71%
- Price
- $45.00
- Shares after
- 6,555,102
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3
ELVN
transaction
Common Stock
Sale
- Transaction value
- $2,104,920
- Shares
- -46,776
- Change %
- -0.71%
- Price
- $45.00
- Shares after
- 6,555,102
- Date
- 22 Jun 2026
- Ownership
- See Footnotes
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
Footnote F2
These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
Footnote F3
This report on Form 4 is filed by OrbiMed Advisors, GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.